Research Article
Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference?
Table 1
Baseline patient characteristics.
| | | BP group () | Non-BP group () | |
| | Age (yr) | 72.6 (58–85) | 73.4 (61–84) | 0.698 | | Female sex | 73 (100%) | 8 (100%) | 1.000 | | Affected side (right : left) | 35 : 38 | 4 : 4 | 1.000 | | Body mass index (kg/m2) | 25.6 (17.3–40.7) | 24.9 (21.2–32.3) | 0.466 | | Bone mineral density (-score, femur) | −2.2 (−0.6–−3.5) | −2.3 (−0.8–−3.7) | 0.589 | | Comorbidities | | | | | Cardiovascular disease | 12 (16.4%) | 2 (25.0%) | 0.621 | | Cerebrovascular disease | 5 (6.8%) | 1 (12.5%) | 0.475 | | Chronic pulmonary disease | 8 (11.0%) | 1 (12.5%) | 1.000 | | Chronic renal disease | 1 (1.4%) | 0 (0.0%) | 1.000 | | Chronic liver disease | 5 (6.8%) | 0 (0.0%) | 1.000 | | Diabetes mellitus | 17 (23.3%) | 2 (25.0%) | 1.000 | | Smoking | 1 (1.4%) | 0 (0.0%) | 1.000 | | Parkinsonism | 1 (1.4%) | 1 (12.5%) | 0.189 | | Cognitive impairment | 3 (4.1%) | 1 (12.5%) | 0.346 | | ASA classification | | | 0.216 | | I or II | 66 (90.4%) | 6 (75.0%) | | | III or IV | 7 (9.6%) | 2 (25.0%) | | | Koval score | | | 1.000 | | 1 | 23 (31.5%) | 3 (37.5%) | | | 2 or 3 | 39 (53.4%) | 4 (50.0%) | | | ≥4 | 11 (15.1%) | 1 (12.5%) | | | Presence of prodromal symptoms† | | | 0.673 | | Yes | 20 (27.4%) | 1 (12.5%) | | | No | 53 (72.6%) | 7 (87.5%) | |
|
|
†Prodromal symptoms before fracture, such as thigh pain.
|
